Molecular Approach to Cancer Management

Dr. Gajanan V. Sherbet is Doctor of Science of London University and Fellow of the Royal College of Pathologists and the Royal Society of Chemistry. He is member of the editorial boards of many scientific and medical journals, and formerly editor of Experimental Cell Biology and Pathobiology. Dr. Sherbet’s major scientific interest is in cancer metastasis. He has focused on the role of growth factors and their signaling, and the calcium binding protein S100A4 in cell proliferation, cancer invasion and metastasis; also he is currently studying the potential of artificial neural networks for predicting breast cancer progression and prognosis. Dr. Sherbet has numerous scientific papers in international journals and has written and edited several books on cancer, such as Growth Factors and Their Receptors in Cell Differentiation, Cancer and Cancer Therapy (2011) and Therapeutic Strategies in Cancer Biology and Pathology (2013), and e-books on the role of growth factors and their receptors in cancer therapy and therapeutic strategies in cancer biology and molecular pathology.

• 1. Modulation of growth factor signaling in targeted therapy: Role of the epidermal growth factor family and their receptors2. The TGF-B family accessory type III receptor function in cancer progression3. Insulin-like growth factor signaling as a target to control tumor progression4. Angiogenesis in neoplasia and antiangiogenesis strategy in the control of tumor growth and metastasis5. On the trail of TRAIL in tumor growth and angiogenesis6. Hedgehog (Hh) signaling in EMT, CSCs and angiogenesis7. Hedgehog is involved in angiogenic signaling by angiopoietin-18. Hippo signaling in cell proliferation, migration and angiogenesis9. Tumor suppression and inhibition of angiogenesis by TXNIP10. Suramin and polysulphonated naphthylureas as angiogenesis inhibitors 11. Quercetin inhibits growth factor signaling: suppresses angiogenesis and cell migration in vitro12. Selenoproteins in cancer control13. Inhibitor of DNA binding proteins in angiogenesis14. Are there gains to be made in exploring anthrax lethal toxin (LeTx) as a tumor and an angiogenesis inhibitor?15. Small molecule inhibitors of angiogenesis and cell proliferation16. Control of tumor growth and angiogenesis by thalidomide and its analogues17. Endogenous inhibitors of angiogenesis18. Metformin and its antitumor attributes19. Statins in cancer biology20. The HMG (High mobility group) proteins in cancer progression21. MTAs in EMT activation and tumor and metastasis promotion22. S100A4 has potential benefits as a therapeutic target23. Notch Signaling in carcinogenesis24. Canonical and non-canonical activation of NF-κB in tumorigenesis25. Stem cells in cancer therapy26. Notable approaches to cancer immunotherapy